GlobeNewswire

GridGain® Joins Confluent Partner Program

Share

GridGain Apache Kafka® Connector Provides Native Integration Between GridGain and Kafka for Streaming Data Applications

FOSTER CITY, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced that the GridGain Apache Kafka® Connector is now verified by Confluent. The connector provides native integration between GridGain and Kafka. The connector makes it simple for GridGain users to leverage the streaming data capabilities of Kafka to create high performance systems that can ingest, process and analyze massive amounts of data at in-memory speeds with massive scalability. With GridGain as the HTAP (hybrid transactional/analytical processing) system and Kafka managing data streams, powerful architectures for digital transformation initiatives such as Internet of Things (IoT) and web-scale applications are possible.

“A growing number of enterprises pair GridGain with Apache Kafka to create high performance, massively scalable solutions for streaming data use cases,” said Terry Erisman, Vice President of Marketing at GridGain. “These systems can power digital transformation initiatives that leverage solutions such as IoT or web-scale applications. We are pleased to have the GridGain Kafka Connector verified as part of the Confluent Partner Program.”

Confluent, provider of the leading streaming platform based on Apache Kafka, designed the partner program to enable a rapidly growing ecosystem around Apache Kafka and Confluent. It is the largest ecosystem of technology vendors, consulting and system integrators as well as authorized training partners offering Kafka-based solutions and services.

“Apache Kafka is a broadly adopted platform for digital transformation initiatives that increasingly require ingesting and processing massive volumes of streaming data for a variety of applications,” said Sid Rabindran, Director, Partner Ecosystem at Confluent. “We are pleased to formalize our technology partnership with GridGain Systems to enable native integration between our two platforms and enable additional use cases.”

Confluent Platform expands Apache Kafka’s integration capabilities, adds tools to optimize and manage Kafka clusters, and makes Kafka easier to build and operate. Confluent Partner Program members have the opportunity to develop robust data connectivity based on the Kafka Connect API, easily build stream processing applications with Kafka’s Streams API, and promote the solutions to customers worldwide.

About Confluent
Confluent, founded by the creators of Apache® Kafka®, provides the leading streaming platform that enables enterprises to maximize the value of data. With a streaming platform that spans to the edges of an organization and captures data into streams of real-time events, businesses in industries such as retail, logistics, manufacturing, financial services, technology and media are able to respond in real time to every customer event, transaction, user experience and market movement whether on premises or in the cloud. Backed by Benchmark, Index Ventures and Sequoia, Confluent is based in Palo Alto, California. To learn more, please visit www.confluent.io. Download Confluent Open Source at www.confluent.io/download.

About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite™. GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. GridGain delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, continuous learning and HTAP. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Kafka, Kafka Apache Ignite, Ignite, Apache Spark, and Spark, are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders22.7.2019 08:00:00 CESTPress release

PRESS RELEASE July 22, 2019 Preclinical candidate SAN903 to be developed to Phase 1 clinical study in 18 months First-in-class compound with a new mode-of-action and strong IP Saniona AB (OMX: SANION) today announces that it has selected a new development candidate, SAN903, for preclinical development, which can enter clinical Phase 1 in only 18 months. Based on work done to date, Saniona has elected to focus SAN903 initially on the treatment of Crohn’s disease and colitis. “SAN903, which is generated from our advanced ion channel platform, is a first-in-class product and, we believe, has the potential to transform the treatment paradigm for severe autoimmune diseases, including Crohn’s disease and colitis. We look forward to bringing this exciting asset to the stage of Phase 1 first-in-man clinical studies in early 2021,” said Jørgen Drejer, CEO of Saniona. With SAN903, Saniona has identified a novel proprietary IK channel inhibitor that effectively dampens gut inflammation and can be

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company22.7.2019 08:00:00 CESTPress release

Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015. The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms in an in vivo setting and to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds. The research collaboration is extended with 6 months until the end of 2019 and the companies have agreed to thereafter use the following 6 months (until end June 2020) to evaluate the potential for a further partnership. Contact information: Per Walday, CEO pw@pcibiotech.no Mobile: +47 917 93 429 About PCI Biotech PCI Biotech is a biopharmaceutical co

Saniona väljer mycket lovande preklinisk kandidat med bred potential i autoimmuna störningar22.7.2019 08:00:00 CESTPressemelding

PRESSMEDDELANDE 22 juli 2019 Preklinisk kandidat SAN903 ska utvecklas till fas 1 inom 18 månader First-in-class substans med ny verkningsmekanism och starkt IP Saniona AB (OMX: SANION) meddelar idag att det har valt en ny läkemedelskandidat SAN903, för preklinisk utveckling som är tänkt att gå in i kliniska fas 1-studier inom 18 månader. Baserat på det forskningsarbete som utförts har Saniona valt att inledningsvis fokusera SAN903 på behandlingen av Crohns sjukdom och kolit. "SAN903, som genererats från vår avancerade jonkanalplattform, är en first-in-class substans och vi tror att den har potential att ändra behandlingsparadigmen för allvarliga autoimmuna sjukdomar inklusive Crohns sjukdom och kolit. Vi ser fram emot att ta denna spännande substans till kliniska fas 1-studier i början av 2021”, säger Jørgen Drejer, vd för Saniona. Med SAN903 har Saniona identifierat en ny proprietär IK-kanalinhibitor som effektivt dämpar tarminflammation och kan användas för behandling av inflammatori

BinckBank publishes its half year report 201922.7.2019 07:15:00 CESTPress release

Highlights of the first half year 2019 Saxo Bank has extended the initial offer period during which shareholders can submit their shares under the Offer to 31 July 2019. The process for obtaining regulatory approvals is on schedule. As mentioned before, the expectation remains that the transaction with Saxo Bank will be completed during the first half of Q3 2019. Net result 19H1 € 6.6 million (18H1: € 22.2 million). Net earnings per share 19H1 € 0.10 (18H1: € 0.33). The result for 18H1 included the profit on the sale of Think ETF Asset Management B.V. (€ 8.1 million, € 0.12 per share). No interim dividend will be paid for the first half of 2019. Number of transactions 19H1 in line with 18H1 at 5.0 million transactions (+1%). Assets under management at the end of 19H1 amounted to € 1.0 billion (18H1: € 1.0 billion). Assets under management of the new propositions rose to € 239 million (18H1: € 142 million). Turning point to net inflow almost reached. Attachment 2019-Q2 half year report

Clariant AG: Clariant signs an agreement regarding the sale of its Healthcare Packaging Business22.7.2019 07:00:00 CESTPress release

Divestment of Clariant’s Healthcare Packaging Business to Arsenal Capital Partners Total consideration of approx. CHF 308 million Muttenz, July 22, 2019 - Clariant, a focused and innovative specialty chemical company, has signed an agreement with respect to the sale of its Healthcare Packaging business to a newly-formed affiliate of Arsenal Capital Partners. The total consideration of the sale amounts to approximately CHF 308 million payable at closing, which is expected in Q4 2019. The total consideration is equivalent to 13.2 times adjusted FY2018 EBITDA. The closing of the transaction is subject to customary conditions and approvals. Clariant’s Healthcare Packaging business offers products used to protect pharmaceutical products from moisture and oxygen. This includes customizable, high-quality drop-in products (canisters and packets), Integrated Desiccant Systems and specially designed plastic bottles containing oxygen barrier materials. In 2018, the Healthcare Packaging business g

Schibsted ASA (SCHA/SCHB) - Mandatory Notification of Trade22.7.2019 07:00:00 CESTPress release

Stiftelsen Tinius, through Blommenholm Industrier AS, has on 19 July 2019 acquired 80,458 B-shares in Schibsted ASA (the “Company”), at a price of NOK 219.5039 per share. After this transaction Blommenholm Industrier owns 28,188,589 A-shares and 29,734,382 B-shares in the Company. Stiftelsen Tinius and Blommenholm Industrier AS is represented in the board of the Company by Ole Jacob Sunde. Oslo, 19 July 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act